Results 141 to 150 of about 19,083 (252)

Association of Body Mass Index with SARS‐CoV‐2 Infection in Inflammatory Arthritis Patients Receiving Biologic Therapy: Singapore National Biologics Register Findings

International Journal of Rheumatic Diseases, Volume 29, Issue 6, June 2026.
ABSTRACT Purpose To determine the association of body mass index (BMI) with incident COVID‐19 infection in patients with inflammatory arthritis (IA) using biologic disease‐modifying anti‐rheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) and to describe characteristics of patients with severe COVID‐19 infection. Methods This prospective
Preeti Dhanasekaran, Siaw Ing Yeo, Yi Xin Ng, Rosa Lim, Stephanie Wong, Stanley Angkodjojo, Andrew Yu Keat Khor, Li Wearn Koh, Manjari Lahiri, Margaret Ma   +9 more
wiley   +1 more source

Reciprocal Regulation of GLI1 and GLI3 Fine Tunes the Pathogenic Behavior of Synovial Fibroblasts in Rheumatoid Arthritis

International Journal of Rheumatic Diseases, Volume 29, Issue 6, June 2026.
ABSTRACT Objective We investigated the role of GLI3, a transcription factor highly expressed in the pathogenic THY1+CD34− sublining subset of rheumatoid arthritis synovial fibroblasts (RASFs), in regulating their pathogenic behavior. Methods GLI3 protein levels were quantified in freshly isolated RASF subsets by Western blotting.
Motohiko Sato, Tetsuya Saito, Yoji Komiya, Seiji Noda, Yasuhiro Tagawa, Akio Yamamoto, Hideyuki Iwai, Kentaro Endo, Hideyuki Koga, Yasuhiro Takahara, Kazutaka Sugimoto, Ichiro Sekiya, Eiryo Kawakami, Tadashi Hosoya, Shinsuke Yasuda   +14 more
wiley   +1 more source

Dosing Biologic Drugs for Patients With Obesity: One Size Does Not Fit All

Arthritis &Rheumatology, Volume 78, Issue 6, Page 1206-1209, June 2026.
Stephen J. Balevic, Daniel Gonzalez, Bernd Meibohm   +2 more
wiley   +1 more source

Predictive Factors for Relapse in Still's Disease: A Retrospective Cohort Study of Clinical and Laboratory Biomarkers

Clinical and Translational Science, Volume 19, Issue 6, June 2026.
ABSTRACT This retrospective cohort study aimed to identify clinical and laboratory predictors of relapse in patients with Still's disease. A total of 94 patients diagnosed by Yamaguchi or Fautrel criteria across two rheumatology centers between 2012 and 2024 were evaluated, of whom 87 were eligible for analysis.
İbrahim Yahya Çakır, Abdulsamet Erden, Yeter Mahmutoğlu, Rıza Can Kardaş, Emine Uslu, Ertuğrul Çağrı Bölek, Serdar Sezer, Müçteba Enes Yayla, Hamit Küçük, Abdurrahman Tufan, Aşkın Ateş, Murat Turgay, Mehmet Akif Öztürk   +12 more
wiley   +1 more source

A Clinical and Economic Review of Disease-Modifying Antirheumatic Drugs

Rheumatoid arthritis is one of the most common chronic systemic inflammatory diseases, affecting approximately 1% of the adult population. Disease-modifying antirheumatic drugs (DMARDs) have been the mainstay of treatment for rheumatoid arthritis when ...
Douglas Coyle, Sherine E. Gabriel, Larry W. Moreland   +2 more
core  

Rheumatoid arthritis: antirheumatic agents

, 2006
https://scholarlycommons.pacific.edu/phs-facbooks/1026/thumbnail ...
Boyce, Eric G.
core  

Clinical Management of Antirheumatic Drug Exposure During Therapeutic Plasma Exchange. [PDF]

Clin Rev Allergy Immunol
Ding Z, Li J, Zhong X.
europepmc   +1 more source

New antirheumatic substance based on phenolic glycoside structure methyl (4-?-?- glucopyranosyloxy)-benzoic acid

, 2016
Rheumatoid arthritis (RA) is a chronic inflammatory multifactorial disorder affecting approximately 1% of population, with over 3000000 new cases annually. The principal pharmacological agents are nonsteroidal anti-inflammatory drugs (NSAID).
Anis Amalina
core  

Interpretable Machine Learning Framework for Predicting Major Adverse Cardiovascular Events in Rheumatoid Arthritis Using Electronic Health Records: Multicenter Cohort Study. [PDF]

JMIR Form Res
Chiang WC, Lin GL, Chang YS, Liu YC, Huang CW, Nguyen PA, Hsu JC, Liou DM, Yang HC.   +8 more
europepmc   +1 more source

Incidence of interstitial lung disease in seropositive rheumatoid arthritis patients receiving biologics, Janus kinase inhibitors, or methotrexate. [PDF]

Ther Adv Musculoskelet Dis
Yoon J, Han M, Song JJ, Lee SW, Jung I, Park YB.   +5 more
europepmc   +1 more source